Skip to content
The Chat Archive
gpt-4o-search-preview· OpenAI LMArena Search Arena 24K

Help me cite the FDA website for the following sentence: At the time of writing this…

  1. User

    Help me cite the FDA website for the following sentence: At the time of writing this review, eleven ICIs have been approved by the Food and Drug Administration (FDA) .

  2. Assistant

    At the time of writing this review, eleven immune checkpoint inhibitors (ICIs) have been approved by the Food and Drug Administration (FDA). These include:

    1. Ipilimumab (Yervoy) – Approved in 2011 for metastatic melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous carcinoma (in combination with Nivolumab).

    2. Nivolumab (Opdivo) – Approved in 2014 for metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin's lymphoma, head and neck cancer, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, esophageal carcinoma, malignant pleural mesothelioma, and gastric cancer.

    3. Pembrolizumab (Keytruda) – Approved in 2014 for metastatic melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin's lymphoma, urothelial carcinoma, gastric cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, small cell lung cancer, esophageal carcinoma, endometrial cancer, squamous cell carcinoma, and biliary tract cancer.

    4. Atezolizumab (Tecentriq) – Approved in 2016 for bladder cancer, non-small cell lung cancer, breast cancer, small cell lung cancer, hepatocellular carcinoma, and metastatic melanoma.

    5. Avelumab (Bavencio) – Approved in 2017 for Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma.

    6. Durvalumab (Imfinzi) – Approved in 2017 for non-small cell lung cancer, small cell lung cancer, and biliary tract cancer.

    7. Cemiplimab (Libtayo) – Approved in 2018 for squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.

    8. Dostarlimab (Jemperli) – Approved in 2021 for endometrial cancer.

    9. Relatlimab in combination with Nivolumab (Opdualag) – Approved in 2022 for previously untreated melanoma that cannot be removed surgically or has metastasized.

    10. Tremelimumab (Imjudo) – Approved in 2022 for hepatocellular carcinoma (in combination with Durvalumab) and non-small-cell lung cancer (in combination with Durvalumab and platinum-based chemotherapy).

    11. Belzutifan – Approved in 2023 for kidney cancer.

    These approvals reflect the FDA's commitment to advancing cancer treatment through immunotherapy.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.

Identical first prompt